Skip to main content
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. — Investor Relations & Filings

Ticker · RDHL ISIN · US7574681034 LEI · 52990034U7FZBKRAOE32 US Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2020-08-05 Regulatory Filings
Country IL Israel
Listing US RDHL

About RedHill Biopharma Ltd.

https://www.redhillbio.com/

RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered, small molecule drugs. The company's primary therapeutic areas of focus are gastrointestinal (GI) diseases, infectious diseases, and oncology. Its key commercial product is Talicia® for the treatment of Helicobacter pylori (H. pylori) infection. RedHill's late-stage clinical development pipeline includes several drug candidates. Among these are Opaganib, a broad-acting, host-directed antiviral and anti-inflammatory agent; RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease; and RHB-107 (upamostat), an oral serine protease inhibitor. A significant part of its strategy involves developing its assets for pandemic preparedness and as medical countermeasures, emphasizing therapies with viral mutation-resistant properties suitable for stockpiling.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release about participation in upcoming conferences but does not contain financial statements or detailed financial data. The document length is short (2124 characters), and it primarily serves as a regulatory update or announcement rather than a full report. According to the rules, Form 6-K filings are typically regulatory filings providing updates or information but not full annual or interim reports. Therefore, this document fits best under Regulatory Filings (RNS).
2020-08-05 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC. It includes a press release about a new agreement but does not contain detailed financial statements or comprehensive financial data. The document length is short (2121 characters), and it primarily serves as a regulatory announcement rather than a full report. According to the rules, Form 6-K filings are typically classified under Regulatory Filings (RNS) as they are miscellaneous regulatory announcements that do not fit other specific categories.
2020-08-03 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release about FDA clearance for a Phase 3 study. Form 6-K is a periodic report for foreign private issuers to disclose material information. The document is short (2142 characters) and primarily serves as a regulatory filing to report current events or press releases, not a full financial report or detailed analysis. It does not contain financial statements or detailed financial data. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2020-07-31 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It is a report pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, which is used by foreign private issuers to report material information between annual reports. The document includes a press release about initiating a global Phase 2/3 study for COVID-19. The length is 2106 characters, which is short and primarily an announcement of a press release rather than a full report. There are no financial statements or detailed financial data included. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories and often includes Form 6-K filings that are announcements or updates.
2020-07-30 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, RedHill Biopharma Ltd., submitted to the SEC. It includes a press release about positive Phase 2 study data publication. Form 6-K is a periodic report for foreign private issuers to disclose material information. The document is short (2148 characters) and primarily serves as a regulatory update with an attached press release. It does not contain comprehensive financial statements or detailed financial analysis. Therefore, it is best classified under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and filings that do not fit other specific categories.
2020-07-28 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., pursuant to SEC rules. It includes a press release about increasing patient access to a product, attached as Exhibit 1. The document is short (2125 characters) and primarily serves as a regulatory filing to report current events or updates by the company. It does not contain financial statements, detailed financial analysis, or comprehensive report content. According to the rules, Form 6-K filings are considered Regulatory Filings (RNS) as they are periodic reports for foreign issuers that do not fit into other specific categories like Annual Reports or Interim Reports. Therefore, the appropriate classification is Regulatory Filings (RNS).
2020-07-27 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.